Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when MBOT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsMicrobot Medical wins Israeli approval for LIBERTY robotic system, opens path to global markets
Filed May 26, 2026 · Period ending May 26, 2026 · ~1 min read
Key Changes
-
high
Israeli Ministry of Health approved LIBERTY Endovascular Robotic System for marketing and commercialization in Israel, marking the company's first regulatory clearance in its home market.
Item 7.01 verify on EDGAR → -
high
Approval enables Microbot to obtain a Free Sale Certificate, which can be used to support regulatory submissions and commercial activities in additional international jurisdictions.
Item 7.01 verify on EDGAR → -
medium
LIBERTY is a robotic system designed for endovascular procedures; Israeli approval represents a key milestone in the company's commercialization strategy.
Item 7.01 verify on EDGAR →
Summary
Microbot Medical announced it received regulatory approval from Israel's AMAR Division to market its LIBERTY Endovascular Robotic System in Israel. This is the company's first home-market clearance for the robotic device designed for minimally invasive vascular procedures. The approval is significant because it allows Microbot to begin commercialization efforts in Israel and, importantly, to obtain a Free Sale Certificate that can accelerate regulatory submissions in other countries.
For retail investors, this represents tangible progress in Microbot's path from development to revenue generation. The Free Sale Certificate is particularly valuable as it demonstrates that a recognized regulatory authority has reviewed and approved the device, which can streamline approvals elsewhere. However, investors should watch for concrete commercial traction: initial sales figures, hospital partnerships, and announcements of regulatory submissions in larger markets like the EU or additional countries will indicate whether this approval translates into meaningful business momentum.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Added in current filing · view on EDGAR → · paraphrased
the Company received regulatory approval from the Israeli Ministry of Health's AMAR Division, the authority responsible for medical device regulation in Israel, which allows the Company to market and commercialize the LIBERTY® Endovascular Robotic System in Israel, and also enables the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Microbot Medical announced it received approval from Israel's medical device regulatory authority to market and sell its LIBERTY Endovascular Robotic System in Israel. This approval also allows the company to obtain a Free Sale Certificate, which can be used to support regulatory submissions and commercial activities in other countries.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 26, 2026, the Company announced that it received regulatory approval from the Israeli Ministry of Health’s AMAR Division, the authority responsible for medical device regulation in Israel, which allows the Company to market and commercialize the LIBERTY® Endovascular Robotic System in Israel, and also enables the Company to obtain a Free Sale Certificate to support submissions and commercial activities in additional jurisdictions.
Microbot Medical obtained approval from Israel's medical device regulatory authority (AMAR Division) to market and sell its LIBERTY Endovascular Robotic System in Israel. This approval also allows the company to obtain a Free Sale Certificate, which can be used to support regulatory submissions and commercial activities in other countries.
Event · Item 9.01 — Financial Statements and Exhibits
Microbot Medical filed an 8-K attaching a press release; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Item 9.01. Financial Statements and Exhibits. (d) Exhibits | Exhibit | Number | Description | 99.1 | Press Release
The 8-K lists a press release as Exhibit 99.1 but provides no details in the filing body about the content or subject matter of that release. Without access to the exhibit itself, the nature and materiality of the disclosure cannot be determined from this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify